Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (8876)	2/26/1999 9:54:00 PM
From: aknahow	Respond to of 17367

FAQs updated as of Feb. 99. (Disregard Link Caption which refers to 98. Just go there and read the changes. New info? They are at 360 accruals. Can't say I really found anything new. But Calendar of Events is updated and appears to have some things of real interest. Bio Partnering conference in Japan. Perhaps Tharos can go. But they are sending Castello. My only experience of dealing with the Japanese was in attempting to negotiate a $100 million dollar line of credit. We eventually got it but not from the U.S. Bank controlled by the Japanese. Hope XOMA does not spend too much time or resources trying to do a deal there. Other meetings also.

To: Bluegreen who wrote (8876)	2/28/1999 11:22:00 AM
From: aknahow	Read Replies (2) \| Respond to of 17367

"Why didn't the trial end in 1998? (2/99) We previously believed that we would reach a prespecified target total mortality number by the end of 1998. However, when the DSMB met in September 1998, they advised us that we should continue the trial into 1999 in order to reach that figure." So back in Sept. the DSMB felt the trials would not reach the prespecified target. Does this mean the rate of increase in mortality was much slower than expected? The accrual rate was much faster than expected at the start of the trial. Since the trial still has not been halted does this mean the target still has not been reached? Did XOMA already met with the FDA as some on Yahooh posted they intended to do prior to a meeting with the DSMB? Note Murphy says Xoma will meet with the DSMB in two weeks, and that Xoma would not narrow it down more than that. Note Doyel at I.R. said they would meet in one week, to a poster at Yahoo. I am also confused on the accruals. If they are just a bit above 360 than accruals have slowed down compared to the total number of new cases being reported in the U.K. Will XOMA say anything meaningful in time to defuse the longer fuse on their non novel, non convertible, floorless, with untested net, financing? I admit the financing is less sinister than I first thought, but if no information of substance is released until May, well we have a problem. And if the trial is negative the financing adds to the downside pressure. I have not called XOMA and do not intend to. I expect them to explain things to all shareholders on their web or in p.r. releases.